A Phase I Study of Anetumab Ravtansine in Combination with Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma

Brief Summary

Type:
Pancreatic

Study Type:
Treatment

Phase:
I

ClinicalTrials.gov Identifier:
NCT03816358

Study #:
STUDY00146146

Start Date:
Oct 05, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03816358

View Complete Trial Details & Eligibility at ClinicalTrials.gov